Phosphorylcholine-Based Contact Lenses for Sustained Release of Resveratrol: Design, Antioxidant and Antimicrobial Performances, and
antimicrobial
antioxidant
free water
in vitro−in vivo correlations
medicated contact lenses
ocular tissue biodistribution
resveratrol
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
21 Dec 2022
21 Dec 2022
Historique:
pubmed:
11
12
2022
medline:
24
12
2022
entrez:
10
12
2022
Statut:
ppublish
Résumé
Design of advanced contact lenses (CLs) demands materials that are safe and comfortable for the wearers and that preserve the normal eye microbiota, avoiding chronic inflammation and biofilm development. This work aimed to combine the natural antibiofouling phosphorylcholine and the antioxidant and prebiotic resveratrol as integral components of CLs that may have the additional performance of preventing oxidative-stress related eye diseases. Different from previous uses of 2-methacryloyloxyethyl phosphorylcholine (MPC) as coating, we explored the feasibility of adding MPC at high proportions as a comonomer of 2-hydroxyethyl methacrylate (HEMA)-based hydrogels while still allowing for the loading of the hydrophobic resveratrol. Homogeneous distribution of MPC along the hydrogel depth (confirmed by Raman spectroscopy) notably increased solvent uptake and the proportion of free water while it decreased Young's modulus. Relevantly, MPC did not hinder the uptake of resveratrol by CLs (>10 mg/g), which indeed showed network/water partition coefficients of >100. Protocols for CLs sterilization and loading of resveratrol under aseptic conditions were implemented, and the effects of tear proteins on resveratrol release rate were investigated. CLs sustained resveratrol release for more than 24 h
Identifiants
pubmed: 36495267
doi: 10.1021/acsami.2c18217
pmc: PMC9782386
doi:
Substances chimiques
Antioxidants
0
Delayed-Action Preparations
0
Resveratrol
Q369O8926L
Phosphorylcholine
107-73-3
Hydrogels
0
Anti-Infective Agents
0
Water
059QF0KO0R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
55431-55446Références
Optom Vis Sci. 2021 Feb 1;98(2):159-169
pubmed: 33534380
Nat Biotechnol. 2012 Sep;30(9):868-875
pubmed: 22885723
ACS Appl Mater Interfaces. 2020 Jul 8;12(27):30198-30212
pubmed: 32574031
J Control Release. 2017 Feb 28;248:96-116
pubmed: 28087407
Biomaterials. 2009 Oct;30(28):4930-8
pubmed: 19560198
Prog Retin Eye Res. 2020 May;76:100804
pubmed: 31756497
Mater Sci Eng C Mater Biol Appl. 2021 Feb;119:111606
pubmed: 33321650
Eur J Pharm Biopharm. 2015 Jun;93:196-204
pubmed: 25864442
J Am Assoc Lab Anim Sci. 2015 Nov;54(6):783-7
pubmed: 26632789
Int J Pharm. 2018 Jun 10;544(1):100-111
pubmed: 29627356
Curr Protein Pept Sci. 2020;21(4):357-368
pubmed: 31429686
CNS Neurol Disord Drug Targets. 2016;15(3):267-91
pubmed: 26553163
Microorganisms. 2020 Jul 13;8(7):
pubmed: 32668575
Invest Ophthalmol Vis Sci. 2015 Feb 10;56(3):1575-84
pubmed: 25670486
J Biomater Sci Polym Ed. 1994;6(5):425-33
pubmed: 7841149
Curr Eye Res. 2016 May;41(5):653-61
pubmed: 26237665
J Ocul Pharmacol Ther. 2020 Jul/Aug;36(6):323-341
pubmed: 32310723
Acta Biomater. 2021 Jul 1;128:262-276
pubmed: 33866034
Materials (Basel). 2020 Feb 20;13(4):
pubmed: 32093241
ACS Appl Mater Interfaces. 2022 Feb 16;14(6):7617-7625
pubmed: 35103465
J Control Release. 2019 Jul 10;305:18-28
pubmed: 31103677
Int J Antimicrob Agents. 2018 Jul;52(1):35-41
pubmed: 29530588
Drug Dev Ind Pharm. 2020 Dec;46(12):1960-1970
pubmed: 32985941
Expert Rev Med Devices. 2006 Mar;3(2):167-74
pubmed: 16515383
Mol Vis. 2011;17:3392-405
pubmed: 22219635
ACS Omega. 2021 Feb 26;6(10):7058-7067
pubmed: 33748619
Cont Lens Anterior Eye. 2004 Dec;27(4):193-208
pubmed: 16303542
Acta Biomater. 2019 Jan 15;84:49-62
pubmed: 30448434
Int J Pharm. 2022 Nov 25;628:122281
pubmed: 36243323
Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110092
pubmed: 31546391
Molecules. 2021 Jan 05;26(1):
pubmed: 33466247
Methods Mol Biol. 2011;731:237-45
pubmed: 21516412
Pharmaceutics. 2021 Apr 11;13(4):
pubmed: 33920327
Biomater Sci. 2020 Feb 21;8(4):1171-1180
pubmed: 31995040
Int J Mol Sci. 2021 May 24;22(11):
pubmed: 34073709
Int J Pharm. 2017 May 30;524(1-2):193-204
pubmed: 28366804
J Biomed Mater Res A. 2019 May;107(5):933-943
pubmed: 30701666
J Pharm Sci. 2007 Apr;96(4):802-13
pubmed: 17080411
Pathogens. 2015 Mar 23;4(1):111-36
pubmed: 25806622
Biosci Trends. 2019;13(4):308-313
pubmed: 31527328
Spectrochim Acta A Mol Biomol Spectrosc. 2017 Apr 5;176:83-90
pubmed: 28081493
Colloids Surf B Biointerfaces. 2021 Mar;199:111539
pubmed: 33387797
Sci Rep. 2014 Jun 27;4:5467
pubmed: 24970710
J Agric Food Chem. 2010 Jul 28;58(14):8246-52
pubmed: 20578705
Int J Pharm. 2018 Dec 20;553(1-2):186-200
pubmed: 30342082
Int J Mol Sci. 2015 Mar 12;16(3):5789-802
pubmed: 25775159
Biointerphases. 2020 Aug 31;15(4):041013
pubmed: 32867505
mBio. 2016 Mar 22;7(2):e00198
pubmed: 27006462
Transl Vis Sci Technol. 2021 Dec 1;10(14):5
pubmed: 34870699
ACS Appl Mater Interfaces. 2020 Apr 8;12(14):16125-16136
pubmed: 32202402
Langmuir. 2021 Jan 26;37(3):1062-1072
pubmed: 33434030
Transl Vis Sci Technol. 2016 Nov 08;5(6):3
pubmed: 27847690
Int J Mol Sci. 2021 Jan 28;22(3):
pubmed: 33525499
J Control Release. 2022 Mar;343:672-702
pubmed: 35176393
Cont Lens Anterior Eye. 2021 Apr;44(2):398-430
pubmed: 33775384
Acta Biomater. 2020 Sep 1;113:101-118
pubmed: 32622052
J Control Release. 2022 Aug;348:431-443
pubmed: 35688348
Biomaterials. 2006 Feb;27(4):567-75
pubmed: 16054682